HEPA News and Press, Hepion Pharmaceuticals Inc.

Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN, N.J., March 03, 2026 (GLOBE NEW...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...

Hepion Pharmaceuticals Inc. (HEPA) is expected to report for Q2 2025

2025-08-06 14:00:33 ET LifeMD Plunges 47% Despite Strong Revenue and Platform Expansion LifeMD, Inc. ( LFMD ) fell 46.79% to lead losses in the PRISM Emerging Healthcare Index , despite reporting strong top-line Q2 growth and operational milestones . Total revenue climbed ...

2025-07-31 13:30:24 ET Applied Digital Surges 33% on Record Revenue and Infrastructure Expansion Applied Digital Corporation ( APLD ) rallied 33.20% to top the PRISM Emerging AI Datacenter & Infrastructure Index after reporting strong fiscal Q4 2025 results . The com...

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori...

2025-06-16 08:45:21 ET More on ContraVir Hepion Pharmaceuticals receives delisting notification from Nasdaq Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion Pharmaceuticals appoints Kaouthar Lbiati...

MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) ...

USD Partners LP representing limited partner interest (USDP) is expected to report for Q1 2025 ViaSat Inc. (VSAT) is expected to report $-0.14 for Q4 2025 DermTech Inc (DMTKQ) is expected to report for quarter end 2025-03-31 IHS Holding Limited (IHS) is expected to report $0.17 for Q1...

2025-05-12 16:36:53 ET More on ContraVir Hepion Pharmaceuticals announces 1-for-50 reverse stock split Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion Pharmaceuticals receives delisting notificati...